Evidence map›Paper›PMID 31078138›Full record

ReviewJournal of biomedical science2019

Basics and applications of tumor-derived extracellular vesicles.

Yu-Ling Tai, Pei-Yu Chu, Bao-Hong Lee, Ko-Chien Chen, Chia-Yu Yang, Wen-Hung Kuo, Tang-Long Shen

Open access · diamondAbstract readReview
In one paragraph

Review in Journal of biomedical science, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 50 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
50citing papers in PubMed, 2 pooled it
2.9field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

50 citing papers in PubMed, 2 syntheses or guidelines pooled it, 71 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Review
  5. Review
  6. Review
  7. Article
  8. Review
  9. Article
  10. Review
  11. Article
  12. Article
  13. Review
  14. Review
  15. Review
  16. Article
  17. Article
  18. Article
  19. Article
  20. SUR7 deletion inJournal of extracellular biology · 2023
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 2 countries.

Yu-Ling TaiDepartment of Plant Pathology and Microbiology, National Taiwan University, Taipei, Taiwan.
Pei-Yu ChuDepartment of Plant Pathology and Microbiology, National Taiwan University, Taipei, Taiwan.
Bao-Hong LeeDivision of Hematology and Oncology, Department of Internal Medicine, Taipei Medical University Hospital, Taipei, Taiwan.
Ko-Chien ChenDepartment of Plant Pathology and Microbiology, National Taiwan University, Taipei, Taiwan.
Chia-Yu YangDepartment of Plant Pathology and Microbiology, National Taiwan University, Taipei, Taiwan.
Wen-Hung KuoDepartment of Surgery, National Taiwan University Hospital, Taipei, Taiwan.
Tang-Long ShenDepartment of Plant Pathology and Microbiology, National Taiwan University, Taipei, Taiwan. shentl@ntu.edu.tw.ORCID http://orcid.org/0000-0001-6264-3608
National Taiwan University · TWNational Taiwan University Hospital · TWTaipei Medical University Hospital · TW

Funding

Ministry of Science and Technology, Taiwan 105-2320-B-002-058-MY3Ministry of Science and Technology, Taiwan 106-2911-I-002-569
6 · The paper itself

Abstract

Extracellular vesicle (EV)-mediated intercellular communication acts as a critical culprit in cancer development. The selective packaging of oncogenic molecules renders tumor-derived EVs capable of altering the tumor microenvironment and thereby modulating cancer developments that may contribute to drug resistance and cancer recurrence. Moreover, the molecular and functional characteristics of cancer through its development and posttreatment evolve over time. Tumor-derived EVs are profoundly involved in this process and can, therefore, provide valuable real-time information to reflect dynamic changes occurring within the body. Because they bear unique molecular profiles or signatures, tumor-derived EVs have been highlighted as valuable diagnostic and predictive biomarkers as well as novel therapeutic targets. In addition, the use of an advanced EV-based drug delivery system for cancer therapeutics has recently been emphasized in both basic and clinical studies. In this review, we highlight comprehensive aspects of tumor-derived EVs in oncogenic processes and their potential clinical applications.

Indexed as

Tumor MicroenvironmentCell CommunicationDrug Delivery SystemsExtracellular VesiclesHumansNeoplasmsOncogenesbiomarkerdrug deliveryEV isolationexosomeExtracellular vesicleshomeostasistumor-derived EVstumor microenvironment

Identifiers

PMID31078138
PMCPMC6511661
OpenAlexW2946544636

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.